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Type 2 Innate Lymphoid Cells in Allergic Disease 
Sean Lund1, Hannah H. Walford1,2 and Taylor A. Doherty*,1 
1Department of Medicine, University of California, La Jolla, CA, USA 
2Rady’s Children’s Hospital of San Diego, Division of Rheumatology, Allergy and Immunology, San Diego, CA, USA 
Abstract: Type II innate lymphoid cells (ILC2) are a novel population of lineage-negative cells that produce high levels 
of Th2 cytokines IL-5 and IL-13. ILC2 are found in human respiratory and gastrointestinal tissue as well as in skin. 
Studies from mouse models of asthma and atopic dermatitis suggest a role for ILC2 in promoting allergic inflammation. 
The epithelial cytokines IL-25, IL-33, and TSLP, as well as the lipid mediator leukotriene D4, have been shown to 
potently activate ILC2 under specific conditions and supporting the notion that many separate pathways in allergic disease 
may result in stimulation of ILC2. Ongoing investigations are required to better characterize the relative contribution of 
ILC2 in allergic inflammation as well as mechanisms by which other cell types including conventional T cells regulate 
ILC2 survival, proliferation, and cytokine production. Importantly, therapeutic strategies to target ILC2 may reduce 
allergic inflammation in afflicted individuals. This review summarizes the development, surface marker profile, cytokine 
production, and upstream regulation of ILC2, and focuses on the role of ILC2 in common allergic diseases. 
Keywords: Allergy, asthma, atopic dermatitis, ILC2, nasal polyps, Type 2 innate lymphoid cells. 
INTRODUCTION 
 Allergic inflammation is characterized by increased Th2 
cytokines including IL-4, IL-5, and IL-13 resulting in tissue 
eosinophilia, epithelial mucus metaplasia, and IgE 
production [1]. Classically, conventional CD4+ Th2 cells 
have been considered as the primary regulators of the 
allergic response through production of Th2 cytokines. 
However, during the past decade, a novel Th2 cytokine-
producing population has been identified resulting in a 
paradigm shift in our understanding of allergic inflammation. 
Type 2 innate lymphoid cells (ILC2) were first described in 
2001 by Fort et al. as non-B/non-T cells that produced IL-5 
and IL-13 in response to IL-25 and expressed MHC class 
IIhigh and CD11cdull [2]. Further, IL-25 administered to RAG1 
knockout mice that lack B or T cells led to eosinophilia and 
increased tissue IL-5 and IL-13 expression suggesting that a 
non-B/non-T cell population was active in vivo. A 
subsequent report showed that an IL-25 responsive non-
B/non-T population produced IL-5 in the lungs of mice and 
expressed CD45R, B220, and Thy1 (-/+), but was negative 
for NK1.1, Ly-6G(GR-1), CD4, CD3, and c-kit [3]. 
Importantly, mice deficient in NK cells, mast cells, and T/B 
cells mounted pulmonary eosinophilia after IL-25 
administration that was not present in RAG2/γc double 
knockout mice, thus demonstrating the importance of γc 
cytokines in the development and/or maintenance of this 
novel population. In 2006, Fallon et al. described the 
expansion of a similar c-kit+ non-B/non-T population in the 
context of a helminthic infection [4]. Further, the authors 
demonstrated that IL-25 was required for expulsion of N. 
brasiliensis and occurred independent of B and T cells. 
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 In 2010, three landmark independent studies further 
characterized the phenotype and function of Th2 cytokine 
producing non-B/non-T cell populations that are now termed 
ILC2 by consensus [5-8]. Moro et al. described a lineage-
negative c-kit+ Sca-1+ lymphoid cell population present in 
the mesenteric fat of mice that produced large amounts of 
IL-5 and IL-13 in response to IL-33 and induced intestinal 
goblet cell hyperplasia after N. brasiliensis infection [7]. The 
cells were termed natural helper cells (NHC). In the same 
year, another report showed that a similar non-T cell 
population termed “nuocytes” was detected in mesenteric 
lymph nodes (MLN) and small intestines of IL-13 reporter 
mice stimulated with IL-25 and IL-33 [5]. Nuocytes 
expanded in vivo after helminth infection in an IL-25 and IL-
33 dependent manner and nuocyte IL-13 was required for 
worm expulsion. The third report similarly described 
lineage-negative IL-13 producing cells termed innate helper 
type 2 cells (Ih2) that were increased in MLN, spleen, liver, 
and lung after N. brasiliensis infection and were sufficient to 
expel worms in the absence of adaptive immunity after 
stimulation with IL-25 [6]. Collectively, these studies 
demonstrated that nuocytes, natural helper cells and innate 
helper type 2 cells (now all termed ILC2) are novel Th2 
cytokine producing cells and set the stage for a potential role 
for ILC2 in allergic disease. In this review, we will highlight 
ILC2 development, regulation, cytokine production, and 
potential roles in allergic diseases both in humans and in 
mice. 
ILC2 DEVELOPMENT 
 ILC2s originate from common lymphoid progenitors 
(CLPs) that were previously known to require inhibitor of 
DNA binding 2 (Id2), Notch, and the IL-7 receptor (IL-7R) 
that signals through the common γ chain (γc) [7, 9-11]. One 
report specifically showed that bone marrow natural helper 
cells develop from common lymphoid progenitors (CLPs) 
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and not from either myeloid or erythroid progenitors, 
confirming that ILC2s are of lymphoid origin [9]. 
Additionally, Moro et al. found a near complete absence of 
c-kit+ Sca-1+ natural helper cells in Id2 knockout mice 
consistent with the requirement of Id2 for innate lymphoid 
cell development [7]. Several studies have since shown that 
mice deficient in either IL-7 or its receptor lack ILC2 [7, 12, 
13]. 
 Notch signaling was previously shown to be required for 
in vitro differentiation from CLPs into nuocytes and a recent 
study demonstrated that high levels of Notch signaling 
trigger ILC2 differentiation from human uncommitted 
thymic progenitor cells, and lower levels trigger a T cell 
program of differentiation [14, 15]. T cell factor 1 (TCF-1) is 
downstream of Notch signaling and was recently shown to 
be critical for the development of functional ILC2 [16]. In 
addition to Notch signaling, the transcription factor RORα 
was also shown to be required for nuocyte differentiation in 
vitro and for IL-25-induced nuocyte expansion and goblet 
cell hyperplasia in vivo [14]. Another report substantiated the 
requirement of RORα for natural helper cell development 
and notably showed that other ILC and Th2 cell responses 
were normal, suggesting more specific ILC2 regulation by 
RORα [17]. 
 Recently, the master Th2 cytokine transcription factor 
GATA3 has been shown to play a critical role in human and 
mouse ILC2 development and function [18-20]. In a recent 
report, GATA3-deficient CLPs did not express RORα or Id2 
mRNA and were not capable of producing IL-5 or IL-13 
[19]. The transcription factor Gfi1 contributes to Th2 cell 
development by stabilizing GATA3 and a recent report 
evaluated the role of Gfi1 in ILC2 development and function 
[21, 22]. Interestingly, loss of Gfi1 led to reduced ILC2 
responsiveness to IL-33 and Gfi1 knockout ILC2 expressed 
low levels of IL-5, but co-expressed IL-13 and IL-17, 
suggesting that Gfi1 contributes to the type 2 effector 
program of ILC2 [22]. Taken together, the development of 
ILC2 from CLPs depends on GATA3-induced Id2 and 
RORα, in addition to Notch and IL-7R signaling. 
ILC2 SURFACE MARKERS 
 Initial studies reported that the common surface markers 
expressed (though to variable levels) by Ih2, nuocytes, and 
NHC included CD45, Thy1.2, CD44, CD69, and c-kit (Table 
1). Distinct phenotypic differences between these three 
populations exist in expression of Sca-1, T1/ST2 and IL-7R〈. 
These differences may reflect tissue and condition specific 
variations in ILC2 phenotype and/or methods of ILC2 
identification. Regardless of some phenotypic distinctions, 
consensus has been reached to identify Ih2, nuocytes, and 
natural helper cells as ILC2 [8]. Human ILC2 were initially 
detected in the gastrointestinal tract, lung, nasal polyp tissue 
and peripheral blood and are defined by expression of the 
prostaglandin D2 (PGD2) receptor CRTH2 [23]. 
 Notably, a separate lineage-negative population of cells 
termed multipotent progenitor type 2 cells (MPP2) was 
discovered in IL-4 reporter mice stimulated with Il-25 and 
was initially included along with other innate Th2 cytokine 
producing cells [24]. However, further work has now clearly 
shown that ILC2 are distinct from MPP2 that can 
differentiate into basophils, macrophages, and mast cells 
[25]. Interestingly, simultaneous activation of both ILC2 and 
MPP2 occurs after IL-25 exposure in vivo demonstrating 
complex parallel pathways that may contribute to type 2 
inflammation. 
UPSTREAM REGULATION OF ILC2 
 ILC2s both respond to and are activated by a number of 
different molecules, including cytokines and other 
inflammatory mediators (Fig. 1). Initial reports demonstrated 
that ILC2 were activated by IL-25 and IL-33 leading to 
robust Th2 cytokine production [2-7]. IL-25 (IL-17E) is a 
member of the IL-17 family and binds specifically to the 
heterodimer of IL-17RB and IL-17RA leading to activation 
of MAP kinase and NF-kB pathways [26]. IL-25 is secreted 
by many cell types including Th2 cells, eosinophils as well 
as epithelial cells [26]. IL-33 is released by the airway 
epithelium and lung macrophages, and binds to T1/ST2, a 
heterodimer of ST2 and the IL-1 receptor accessory protein 
(T1) [27-29]. IL-33 exists in a biologically active pro-form 
as well as a processed cleaved protein. The binding of IL-33 
to T1/ST2 leads to p38 MAPK as well as NF-κB signaling 
[27]. Both IL-25 and IL-33 are induced in allergic lung 
inflammation and thus are available for potent ILC2 
stimulation [13, 29-32]. One report recently demonstrated 
that IL-33 is more potent than IL-25 to activate IL-13 
producing ILC2 and induce airway hyperresponsiveness in 
allergen challenged mice [33]. Consistent with this, another 
report showed that ST2 knockout mice, but not IL-17RB 
Table 1. Surface Marker Profiles and Tissue Distribution of Mouse and Human ILC2. Shared Surface Marker Expression As Well 
As Distinctions Among ILC2 Subsets are Shown 
 
 Subtype Tissue Localization Surface Markers References 
Mouse 
Ih2, NHC, Nuocyte shared markers CD45, Thy1.2 (CD90.2), CD44, CD69, c-kit [5-7, 25] 
Ih2 bone marrow, liver, lung, mesenteric lymph node, peritoneum, spleen CD25, CD122  [6] 
NHC fat-associated lymphoid clusters, bone marrow, lung CD25, CD27, CD38, IL-7Rα, Sca-1, T1/ST2, GITR  [7, 9, 13, 37] 
Nuocyte bone marrow, lung, mesenteric lymph node, spleen  
CD43, CD49d, CD127, CD132, IL-7Rα, Sca-1, 
T1/ST2, MHC-II, Itgb7, ICOS, ICAM-1, CCR9 [5, 33, 55] 
Human  ILC2  nasal polyps, sinus epithelium, peripheral blood, lung, gastrointestinal tract 
CD7, CD25, CD62L, CD127, CD161, CRTH2, ST2 
(IL-33R), ALX, CMKLR1, NKG2D, c-kit, DR3 [13, 18, 23, 39, 45] 
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knockout mice, were impaired in allergic sensitization to 
house dust mite [34]. Though IL-33 appears to play a 
dominant role in some settings, both IL-33 and IL-25 induce 
different routes of activation of ILC2s that may depend on 
the availability of these cytokines from different cell types. 
 Aside from IL-25 and IL-33, more recent work has 
identified other mediators of ILC2 activation. TSLP is an 
epithelial cytokine induced in allergic inflammation and 
previously shown to induce conventional Th2 cell priming 
through the costimulatory action of OX40 ligand expressed 
on dendritic cells [35, 36]. Subsequently, a role for TSLP in 
activation of ILC2 was demonstrated as purified human 
peripheral blood and nasal polyp ILC2 cultured with TSLP 
and IL-33 displayed enhanced IL-4, IL-5, and IL-13 
production above IL-33 alone [18]. TSLP has also been 
shown to activate mouse lung and skin ILC2 [37, 38]. 
 Interestingly, recent reports have shown that a number of 
eicosanoids, arachidonic acid-derived lipid mediators, that 
are elevated in allergic inflammation can either directly 
stimulate or inhibit ILC2 [39-41]. Barnig et al. demonstrated 
that PGD2 (binds to CRTH2 expressed on human ILC2) 
potentiated peripheral blood ILC2 IL-13 production above 
IL-2, IL-25, and IL-33 in vitro [39]. Furthermore, this effect 
was lost upon the addition of lipoxin A4 (LXA4) suggesting 
that LXA4 has an inhibitory effect on human ILC2. In 
addition to PGD2 stimulation of ILC2 cytokine production, 
we have also detected increased human peripheral blood 
ILC2 chemotaxis in response to PGD2 [42]. Further, we 
have shown that mouse lung ILC2 express the cysteinyl 
leukotriene 1 receptor (CysLT1R) that is preferentially 
activated by leukotriene D4 [40]. Leukotriene D4 potently 
induced calcium influx and Th2 cytokine production from 
purified lung ILC2 in vitro, and potentiated ILC2 
proliferation and lung eosinophilia in RAG2 knockout mice. 
The eicosanoid molecules including prostaglandins, 
leukotrienes and lipoxins are largely produced by 
macrophages, mast cells, eosinophils and dendritic cells and 
thus represent novel pathways through which ILC2 can be 
activated [41]. 
 The TNF superfamily member TL1A binds to Death 
receptor 3 (DR3) and signals through TRADD and the 
intracytoplasmic death domain [43]. TL1A is produced by 
dendritic cells and macrophages in response to TLR and Fc 
receptor cross-linking and is also produced by T cells in 
response to TCR stimulation [44]. TL1A/DR3 costimulation 
of T cells was previously shown to be required for 
generation of a Th2 response and development of allergic 
lung inflammation in OVA models of asthma [44]. Yu et al. 
have recently reported that TL1A also directly activates 
ILC2 and synergizes with IL-25 in vivo to promote cytokine 
production and increase numbers of ILC2s [45]. Further, 
Dr3-/- mice showed an impaired ability to clear 
Nippostrongylus brasiliensis infection and had reduced ILC2 
levels and lung inflammation compared with WT mice. The 
activation of ILC2 by TL1A provides new insight into 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Interactions and functions of airway ILC2. ILC2 respond to epithelial cytokines TSLP, IL-33, and IL-25 and in turn produce Th2 
cytokines. Additional ILC2 stimulation may occur from PGD2 and leukotriene D4 produced by mast cells and macrophages, and inhibitory 
signals from lipoxin A4. TL1A is also produced by dendritic cells and macrophages and can activate ILC2. ILC2 IL-5 production stimulates 
eosinophil activation and survival, whereas ILC2 IL-13 induces airway hyperresponsiveness, and along with IL-9, promotes mucus 
production. ILC2 IL-4 may contribute to Th2 cell differentiation and amphiregulin secreted by ILC2 binds to EGFR in the airway epithelium 
to induce repair responses. 
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mechanisms of ILC2 activation as TL1A is available at 
mucosal sites including the lung and could synergize with 
known ILC2 activators. 
 Recently, IL-9 was shown to play a critical role in ILC2 
survival [46]. The authors found that IL-9 is an autocrine 
factor necessary for amphiregulin, IL-5, and IL-13 
production, as well as eosinophil recruitment [46]. IL-9R-/- 
mice had reduced tissue repair responses, and this work 
further highlights the potential importance of ILC2 in tissue 
protective roles. The authors hypothesized that the 
antiapoptotic protein BCL3 could be conferring survival to 
ILC2 by inhibiting cell apoptosis associated with activation 
[46]. 
ILC2 CYTOKINE PRODUCTION 
 ILC2s were initially described to produce high levels of IL-5 
and IL-13 and very low levels of IL-4 in response to IL-33 in 
vitro [5, 7]. Interestingly, this cytokine pattern (high IL-5, IL-13 
and low IL-4) may be more related to the effects of IL-33 as 
conventional T cells stimulated with IL-33 develop into IL-5 
producing cells that do not produce IL-4 [47]. Subsequently, 
studies have shown that ILC2 stimulated with TSLP and 
leukotriene D4 produce IL-4 suggesting that ILC2, under 
certain conditions, are a source of IL-4 [18, 40]. Interestingly, 
lung ILC2 have recently been shown to constitutively produce 
IL-5 critical to eosinophil homeostasis, though IL-13 production 
requires IL-25 or IL-33 stimulation [48]. As stated above, ILC2 
highly express the master Th2 cytokine transcription factor 
GATA3 that is required for ILC2 Th2 cytokine production [13, 
18-20]. Though conventional Th2 cells and ILC2 share GATA3 
expression, ILC2 express GATA3 in the bone marrow 
suggesting they are primed for Th2 cytokine production without 
peripheral differentiation [13, 20]. Importantly, a recent study 
demonstrated that TSLP further enhances GATA3 expression in 
human ILC2, and thus may be one mechanism of ILC2 Th2 
cytokine production induced by TSLP [18]. 
 ILC2 have also been shown to produce IL-6, IL-9, and the 
EGFR ligand amphiregulin [7, 32, 49, 50]. IL-9 contributes to 
many features of allergic asthma in animal models including 
airway eosinophilia and mucus production [51]. Lung ILC2 
from mice challenged with the protease allergen papain were 
found to be a dominant source of IL-9 dependent on IL-2, and 
ILC2 cultured with IL-9 showed increased production of IL-5, 
IL-6, and IL-13 [50]. Amphiregulin is produced by ILC2 after 
airway administration to mice of influenza virus and the fungal 
allergen Alternaria [32, 49]. In mice receiving influenza virus, 
ILC2 amphiregulin promoted lung tissue repair suggesting that 
ILC2 may contribute to both pathogenic and healthy remodeling 
responses in the lung [49]. Finally, the alternatively activated 
macrophage enzyme Arginase I is constitutively produced by 
ILC2s though deletion of the Arginase I gene does not appear to 
inhibit cytokine production, proliferation or survival of ILC2s 
[52]. Overall, these reports suggest that the variable cytokine 
production by ILC2 during lung responses may play distinct 
roles depending on the inflammatory context. 
ILC2 LOCALIZATION IN TISSUES 
 ILC2 have been found in several different anatomical 
locations and have been studied in various mouse models of 
disease (Table 1). Studies in mice have shown ILC2 to be 
present in lung, skin, mesenteric lymph nodes, bone marrow, 
liver, spleen, gastrointestinal tract and in mesenteric fat-
associated lymphoid clusters [5-7, 9, 28, 38]. Interestingly, 
lung IL-5 positive ILC2 are localized to the collagen rich 
regions of the conducting airways, but not in alveolar spaces 
[48]. In humans, ILC2s have been found in nasal polyps, 
sinus epithelium, peripheral blood, lung, and in the 
gastrointestinal tract [18, 23, 49]. Thus, the extensive 
distribution of ILC2 in tissues suggests that ILC2 may 
contribute to many organ specific type 2 inflammatory 
responses. 
ROLES OF ILC2 IN ALLERGIC DISEASE 
 The roles and regulation of ILC2 in the following allergic 
diseases are summarized in Table 2. 
ILC2 in Mouse Models of Asthma 
 Mouse models of asthma induced by allergens or viruses 
are characterized by features found in human asthma 
including airway hyperresponsivness, peribronchial 
inflammation, epithelial mucus production and airway 
remodeling. Several studies have demonstrated the 
importance of ILC2s in different mouse models and are also 
reviewed elsewhere [53, 54]. ILC2 have been shown to 
contribute to type 2 lung inflammatory responses and airway 
hyperresponsiveness (AHR) in mice infected with influenza 
virus and after challenge with multiple allergens including 
Alternaria, papain, house dust mite and OVA [12, 13, 28, 37, 
55, 56]. The initial report by Chang et al. showed that ILC2 
IL-13 production was required for AHR induced by 
influenza virus as adoptive transfer of wild type ILC2, but 
not IL-13 knockout ILC2, restored AHR in ILC2 depleted 
mice [28]. Another report demonstrated that the numbers of 
IL-5 and IL-13 producing lung ILC2 were shown to be 
equivalent to conventional cytokine producing Th2 cells in 
mice challenged with house dust mite [56]. Our group and 
others have reported that intranasal administration of the 
fungal allergen Alternaria alternata rapidly induces IL-33, 
activation of lung ILC2, and airway eosinophilia dependent 
on IL-33 signaling [12, 32]. Further, we found that ILC2 
express receptors for IL-4 and IL-13 and proliferation was 
impaired in STAT6 deficient mice suggesting either a direct 
or indirect regulation of ILC2 by the IL-4/IL13/STAT6 axis. 
A single challenge with Alternaria given to mice also 
induces rapid cysteinyl leukotriene production dependent on 
STAT6 that may further regulate ILC2 activation and/or 
proliferation [40]. 
 Though ILC2 appear to direct pathogenic lung responses 
in asthma models, there is evidence that ILC2 may promote 
tissue repair after viral and allergen challenges. In ILC2-
depleted RAG-deficient mice infected with influenza, there 
was significant impairment in post infection epithelial barrier 
regeneration that was restored upon ILC2 transfer [49]. 
Importantly, the EGFR ligand amphiregulin was highly 
produced by ILC2 and was sufficient to induce epithelial 
repair after ILC2 depletion. In addition to influenza virus, 
Alternaria alternata intranasal challenges to induce ILC2 
production of amphiregulin and upregulate the amphiregulin 
receptor EGFR supporting a role for ILC2 in tissue repair 
post allergen challenge as well [13]. Thus, ILC2 may have 
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both harmful as well as beneficial effects in lung 
inflammation. ILC2 are activated both by epithelial-derived 
cytokines such as IL-25, IL-33, and TSLP as well as 
leukotrienes found elevated in asthma, and yet ILC2 also 
produce amphiregulin, an important tissue repair mediator. 
Airway ILC2 responses and upstream mediators are shown 
in Fig. (1). Further research is needed to elucidate the 
relative contribution of ILC2 during development and 
resolution of inflammatory responses as well as tissue repair. 
ILC2 in Human Asthma 
 ILC2 have not been studied extensively in human 
asthma, though ILC2 as well as upstream cytokines and 
mediators including IL-33, leukotrienes, and PGD2 have 
been detected in human lungs [39, 49, 57, 58]. In 2001, a 
report showed that human asthmatics had increased serum 
T1/ST2 receptor during acute exacerbation [59]. Subsequent 
studies have shown increased levels of IL-25, IL-33, and 
TSLP in patients with asthma [58, 60, 61] that all have the 
potential to active ILC2. In 2009, a landmark study reported 
the presence of a CD34+ non-B/non-T lymphocyte 
population found in asthmatic sputum that produced IL-5 
and IL-13 in response to inhalational allergen challenge [62]. 
Whether or not these cells are the same as CRTH2-
expressing ILC2 found later in human lungs is not clear. 
Taken together, these studies suggest that ILC2 may play a 
significant role in human asthma especially given the 
heterogeneity of asthma triggers apart from allergens 
including tobacco smoke, viruses, and ozone that could 
activate innate pathways. 
ILC2 in Chronic Rhinosinusitis 
 Chronic rhinosinusitis (CRS) is an inflammatory 
condition involving the mucosal lining of the nose and 
paranasal sinuses, estimated to affect 2% to 5% of the adult 
general population and is often associated with asthma, 
aspirin sensitivity, cystic fibrosis and allergic disease [63]. 
Chronic rhinosinusitis with nasal polyps (CRSwNP) 
represents a distinct disease entity from chronic 
rhinosinusitis without nasal polyps (CRSsNP). In 2011, 
ILC2 were first reported to be enriched in nasal polyps 
suggesting a potential role for these cells in CRSwNP [23]. 
A subsequent study identified an increased percentage of 
ILC2 in inflamed sinonasal mucosa (not polyp tissue) from 
patients with CRSwNP as compared to CRSsNP [64]. 
Further work has shown that ILC2 from nasal polyps 
produce IL-13 in a GATA3-dependent manner after culture 
with IL-2, IL-33 and TSLP [18]. Additionally, epithelial 
cells from patients with CRSwNP show high levels of 
mediators that regulate ILC2 including TSLP and IL-33[64, 
65]. Further, TSLP enhanced the level of ILC2 GATA3 
expression that may account for increased cytokine 
production [18]. Interestingly, ectopic expression of GATA3 
by retrovirus of Lin-CD127+CD117+NKp44-CRTH2- cells 
resulted in the induction of surface CRTH2, T1/ST2, and 
TSLP-R as well as IL-13 production in response to TSLP 
and IL-33. This work critically demonstrates the role of 
GATA3 in directing human ILC2 programming. 
 A recent consensus report suggests the importance of 
endotypes within CRSwNP patients defined by 
histopathologic features, cytokine profiles and presence of 
different cell types [66]. Though a large portion of nasal 
polyps contain high numbers of eosinophils and correlate 
with elevated Th2 cytokine levels, there is increasing 
recognition that polyps have varying cellular predominance 
due to distinct pathogenic mechanisms [67]. We have 
recently found that eosinophilic nasal polyps from allergic 
individuals have a higher percentage of GATA3-expressing 
ILC2 as compared to non-eosinophilic nasal polyps from 
individuals with unknown allergic status (unpublished data), 
thus further implicating ILC2 in the development of 
eosinophilic CRSwNP. 
ILC2 in Atopic Dermatitis 
 Atopic dermatitis is a chronic inflammatory skin condit-
ion associated with skin barrier disruption, eosinophilic 
infiltration and high serum IgE levels. Recently, studies have 
Table 2. Regulation and Function of ILC2 in Mouse Models and Human Allergic Disease 
 
 Allergic Disease ILC2 Upstream Regulation ILC2 Function Role of ILC2 in Disease References 
Mouse 
Asthma 
IL-25 
IL-33 
LTD4 
TSLP 
TL1A  
IL-4, IL-5, IL-9, IL-13, 
amphiregulin  
AHR, eosinophilia, mucus 
production, tissue repair  [12, 13, 28, 33-37, 40, 49, 55, 56] 
Atopic Dermatitis IL-33 TSLP IL-4, IL-5, IL-13 
orthokeratosis, acanthosis, 
skin lesions, eosinophilia [38, 68, 69] 
Human 
Asthma 
IL-25 
IL-33 
LXA4 
PGD2 
TSLP 
IL-13 production from 
peripheral blood ILC2 ? [39, 49, 57-62] 
Atopic Dermatitis IL-33 TSLP ? ? [38, 69, 71] 
Chronic 
Rhinosinusitis 
IL-33 
TSLP IL-13  ? [18, 23, 64, 65] 
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reported the presence of ILC2 in healthy mouse skin [38, 
68]. In one report, ILC2s have been classified as dermal 
ILC2 (dILC2), and differ slightly from those found in other 
organs as dILC2 express CD103 and lack expression of c-Kit 
[68]. The same study used a dsRed/IL-13 transgenic reporter 
and determined that the majority of cells positive for IL-13 at 
steady state were CD3- cells, ruling out Th2 cells as primary 
contributors to homeostatic IL-13 production in the skin. 
Another group utilized a mouse model of TSLP-driven 
atopic dermatitis and demonstrated that ILC2 activation 
occurs independent of IL-33, but is dependent on TSLP 
receptor signaling [38]. In contrast, a separate report 
demonstrated that overexpression of IL-33 in the skin led to 
atopic dermatitis-like pathology including increased dermal 
eosinophils, increased Th2 cytokines and expansion of skin 
ILC2 [69]. Thus, the availability of specific upstream 
mediators of ILC2 activation likely dictates the dominant 
pathway resulting in ILC2 accumulation and cytokine 
production. Studies of ILC2 in human atopic dermatitis are 
limited, though similar to asthma and chronic rhinosinusitis, 
elevation of TSLP and IL-33 is present in human atopic 
dermatitis [70, 71] and one recent report demonstrated that 
ILC2 are increased in skin lesions of atopic dermatitis 
patients compared with controls [38]. Thus, ILC2 may play a 
role in atopic dermatitis but investigations into skin ILC2 
function from diseased and non-diseased humans are needed. 
ILC2 INTERACTIONS WITH OTHER CELL TYPES 
 Recently, several studies have suggested that interactions 
between ILC2 and other cell types including CD4+ T cells, 
B cells, and mast cells may have meaningful effects on ILC2 
levels or function. Data from the initial studies of mesenteric 
fat-associated ILC2 support a role for dependence on IL-2 
for ILC2 cytokine production [7]. Subsequently, lung ILC2 
were shown to require IL-2 for costimulation of cytokine 
production in vitro and ILC2 IL-9 production required IL-2 
from adaptive immune cells in vivo [37, 50]. T cells are a 
known source of IL-2 and this suggests that adaptive 
immune cells are involved in the maintenance of ILC2 
responses. ILC2 have also shown the capacity to produce IL-
4 after stimulation with TSLP and leukotriene D4, and thus 
could provide an important signal leading to Th2 cell 
polarization [18, 40]. Interestingly, leukotriene production 
by dendritic cells has been shown to be required for Th2 
responses to house dust mite suggesting that a 
leukotriene/IL-4 axis could induce Th2 cell priming and 
perhaps ILC2 are involved in this pathway [72]. Direct 
contact between ILC2 and CD4+ T cells may occur as some 
ILC2 populations have been shown to express MHCII [5], 
though the low numbers of ILC2 in tissues and lymph nodes 
do not support a robust pathway where ILC2 present antigen 
to CD4+ T cells. 
 ILC2 were initially described to produce IL-5 and IL-6 
that induced B1 B cells to produce IgA antibody [7]. 
Recently, a report of a Sca-1+ Thy1+ ILC2 population in the 
spleens of mice that does not express IL-7R or T1/ST2, but 
expresses IL-18R, was shown to induce IgE production by B 
cells after co-culture with ILC2 and IL-18 [73]. Thus, ILC2 
may amplify B cell IgE responses that are characteristic of 
adaptive Th2 responses. Finally, the costimulatory molecule 
ICOS has also been shown to be expressed by ILC2 and 
could lead to interactions with ICOS-ligand expressing B 
cells [5]. 
 A recent report also demonstrated that ILC2 are co-
localized with mast cells in the dermis [68]. The authors 
tracked the movements of ILC2s using intravital multiphoton 
microscopy and found that interactions between mast cells 
and ILC2 lasted as long 30 minutes. Interestingly, the 
authors also found that IL-9 enhanced mast cell release of 
IL-6 and TNFα, while IL-13 had the opposite effect and 
suppressed mast cell release of IL-6 and TNFα. Another 
report demonstrated the presence of ILC2 in close proximity 
to mast cells in human lung, supporting potential ILC2/mast 
cell interactions [39]. The interactions between ILC2 and 
mast cells could have important influences on shaping 
allergic responses as mast cell mediators including PGD2 
and leukotrienes can activate ILC2 and mast cells could be 
reciprocally modulated by ILC2 cytokines. 
SUMMARY 
 The classic paradigm underlying allergic disease has 
been characterized by allergen specific Th2 cell production 
of IL-4, IL-5 and IL-13 leading to tissue eosinophilia, mucus 
production, and specific IgE production. Though the Th2 
adaptive response to allergen exposure is well substantiated, 
recent evidence suggests that ILC2 may also contribute to 
pathogenic allergic inflammation. The evolutionary 
advantage of tissue ILC2 likely stems from an important 
early role in anti-parasitic immunity. In 2010, the 
identification of nuocytes, innate helper type 2 cells and 
natural helper cells as major players in type 2 immunity 
during helminth infections has led to investigations into 
ILC2 in allergic disease. ILC2, like other innate cells, do not 
require antigen experience and peripheral differentiation and 
thus could drive innate type 2 responses to viruses, tobacco 
smoke, and pollutants associated with asthma. Many 
important questions regarding the role of ILC2 in allergic 
diseases remain including how ILC2 contribute to ongoing 
allergic inflammation in the presence of intact adaptive 
immunity or how ILC2 can be specifically targeted 
therapeutically. Future studies aimed at addressing these 
questions will provide significant insight into mechanisms of 
ILC2 biology and their contributions to human disease. 
ABBREVIATIONS 
AHR = Airway hyperresponsiveness 
CRTH2 = Chemoattractant receptor homologous  
   molecule expressed on TH2 lymphocytes 
DR3 = Death receptor 3 
EGFR = Epidermal growth factor receptor 
GATA3 = Transacting T cell specific transcription factor 3 
ICOS = Inducible T-cell Costimulator 
IgA = Immunoglobulin A 
IgE = Immunoglobulin E 
ILC2s = Type 2 innate lymphoid cells 
PGD2 = Prostaglandin D2 
STAT6 = Signal transducer and activator of transcription 6 
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